Developing a new treatment for adenoviral eye infections
Official title: Translational studies to advance Filociclovir to IND submission for the treatment of adenoviral conjunctivitis and acute keratoconjunctivitis
Funded at Microbiotix, INC · NIH-11037317 · Data updated 2026-11-12
This study is testing a new eye drop treatment for adenoviral conjunctivitis, which is an eye infection that currently has no good options for help, and it's aimed at people who suffer from this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Microbiotix, INC NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $674,963 |
| NIH project number | 1R33EY036947-01 |
| Project ID | NIH-11037317 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing symptoms of adenoviral conjunctivitis or epidemic keratoconjunctivitis.
✕Less likely to help
Patients with non-adenoviral eye infections or those who do not have symptoms of conjunctivitis may not benefit from this research.
What this research studies
This research focuses on advancing filociclovir (FCV) as a treatment for adenoviral conjunctivitis and epidemic keratoconjunctivitis, which currently have no effective therapies. The project aims to complete necessary preclinical studies and finalize the formulation of eye drops that can effectively target these infections. By using animal models, the researchers will confirm the efficacy and safety of the treatment before submitting it for FDA approval. This work is crucial as adenoviral infections can lead to significant visual impairment and economic loss.
Why it matters
Potential benefit: If successful, this research could provide a much-needed effective treatment for patients suffering from adenoviral eye infections.
How similar studies have gone: Previous studies have shown promise in developing antiviral treatments for ocular infections, but this specific approach with filociclovir is novel.
Where this research is happening
-
Microbiotix, INC
Worcester, United States Active
Researchers
- Principal investigator: Bowlin, Terry L. — Microbiotix, INC
- Study coordinator: Bowlin, Terry L.
Related research
Other NIH-funded projects on the same topics.
-
Novel Benzyl-Piperidine antifungals to fight hard-to-treat mucormycosis
A new drug candidate series called Benzyl-Piperidines is being developed to treat invasive mucormycosis, a deadly fungal infection often affecting people with weakened immune systems.
-
Well-tolerated new drugs to fight drug-resistant CMV in transplant patients
A new class of CMV drugs that are easier to tolerate is being developed to prevent or treat CMV infections in people who have had solid organ or bone marrow transplants.
-
Discovery of small-molecule inhibitors to stop bunyavirus endonuclease
A small-molecule approach is being developed to block a key enzyme of bunyaviruses like Rift Valley fever, with the goal of preventing or treating infections in people and animals.
-
Filociclovir eye drops for adenoviral conjunctivitis and epidemic keratoconjunctivitis
This project is developing an antiviral eye drop, filociclovir, to treat adenovirus eye infections like conjunctivitis and the more severe epidemic keratoconjunctivitis.
-
Finding new treatments for a dangerous mosquito-borne virus.
This study is working on new antiviral medicines to help fight the Rift Valley Fever Virus, which can make people very sick, by creating tiny molecules that stop the virus from spreading, since there are no approved treatments or vaccines for it yet.
-
Creating new treatments for antibiotic-resistant bacteria
This study is working on creating new treatments to help fight infections caused by tough bacteria that don't respond to regular antibiotics, so patients can have better options for getting better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.